1173004
doi
10.5281/zenodo.1173004
oai:zenodo.org:1173004
user-sgc-opennotebook
Mizio Matteucci
University of Oxford
Paul E. Brennan
University of Oxford
Alex N. Bullock
University of Oxford
Purification of ACVR1 for co-crystallisation with LDN-193189 and other compounds
Roslin Adamson
University of Oxford
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
purification, ACVR1, LDN-193189, crystallisation
<p>Purification of constitutively active ACVR1 for co-crystallisation with LDN-193189 and three other compounds.</p>
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z].
Zenodo
2018-02-14
info:eu-repo/semantics/other
1173003
user-sgc-opennotebook
1579893801.253405
1756363
md5:a5eb287ec0c0fecdb85ecc53f6e53d89
https://zenodo.org/records/1173004/files/Purification of ACVR1 for co_crystallisation with LDN_193189 31_01_2018_1.docx
public
10.5281/zenodo.1173003
isVersionOf
doi